Drug Profile
Necitumumab - Eli Lilly and Company
Alternative Names: IMC-11F8; LY 3012211; Portraza; PortrazzaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ImClone Systems
- Developer AstraZeneca; Eli Lilly and Company
- Class Antineoplastics; Fab fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase II Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 03 Jun 2022 Updated efficacy data from a phase I trial in Non-small cell lung cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 09 May 2022 Eli Lilly and AstraZeneca completes a phase-I clinical trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, France, Spain, Taiwan, Italy, South Korea (IV) (NCT02789345)
- 26 Apr 2022 Necitumumab is still in phase-II trials for Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain (IV) (EdudraCT2018-003974-29) (NCT03944772)